"....there is also a whole lot of potential in the 'First Warning System'; especially with the current news headlines regarding breast cancer detection and the risks of radiation.
The continuous dilution limits the potential upside after any positive news from the FDA, but if the agency is satisfied with the current information provided and doesn't ask for additional data, then Lifeline will quickly file a 501k and nice move in price should still be in order - in my opinion.
It's a dog-eat-dog world out there for small start-ups, but with a product that boasts the potential of 'FWS', the future should be a bright one for Lifeline and its shareholders - dilution or no dilution."
December 7, 2009: Lifeline Biotech: A crapshoot or a great deal for investors? (Links to past articles about LLBO)
LLBO is currently trading at 0.0028
No comments:
Post a Comment